Exploring the potential of isatin hybrids as anticancer agents: recent advances and future prospective

IF 2.6 4区医学 Q3 CHEMISTRY, MEDICINAL

Medicinal Chemistry Research Pub Date : 2025-02-17 DOI:10.1007/s00044-025-03385-6

Parveen Gahlyan, Tanisha Chauhan, Priyanka Jhajharia, Balaram Pani, Rakesh Kumar

{"title":"Exploring the potential of isatin hybrids as anticancer agents: recent advances and future prospective","authors":"Parveen Gahlyan, Tanisha Chauhan, Priyanka Jhajharia, Balaram Pani, Rakesh Kumar","doi":"10.1007/s00044-025-03385-6","DOIUrl":null,"url":null,"abstract":"<div><p>Synthesis of hybrid molecules via molecular hybridization technique has been known to be a promising strategy which involves the blending of two pharmacophoric groups joined via covalent bonds to make a single entity that can serve as chemotherapeutic agents. “Isatin” is an important toolbox for medicinal chemists with high pharmacological profile being known as the “privileged scaffold” in the field of drug development. Various drugs consisting of isatin core have been shown to have pronounced therapeutic effects on several cancers as they have prophylactic role towards free radicals that cause cancer. This report highlights the most recent advances from the past four years in the development of isatin based drugs against several human cancer cell lines such as MCF-7 (breast cancer cell line), A-549 (lung cancer cell line), Hep-G2 (liver cancer cell line) and some other cell lines, respectively.</p><div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":699,"journal":{"name":"Medicinal Chemistry Research","volume":"34 4","pages":"827 - 848"},"PeriodicalIF":2.6000,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicinal Chemistry Research","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s00044-025-03385-6","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

Abstract

Synthesis of hybrid molecules via molecular hybridization technique has been known to be a promising strategy which involves the blending of two pharmacophoric groups joined via covalent bonds to make a single entity that can serve as chemotherapeutic agents. “Isatin” is an important toolbox for medicinal chemists with high pharmacological profile being known as the “privileged scaffold” in the field of drug development. Various drugs consisting of isatin core have been shown to have pronounced therapeutic effects on several cancers as they have prophylactic role towards free radicals that cause cancer. This report highlights the most recent advances from the past four years in the development of isatin based drugs against several human cancer cell lines such as MCF-7 (breast cancer cell line), A-549 (lung cancer cell line), Hep-G2 (liver cancer cell line) and some other cell lines, respectively.

Abstract Image

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Medicinal Chemistry Research 医学-医药化学

CiteScore

4.70

自引率

3.80%

发文量

162

审稿时长

5.0 months

期刊介绍： Medicinal Chemistry Research (MCRE) publishes papers on a wide range of topics, favoring research with significant, new, and up-to-date information. Although the journal has a demanding peer review process, MCRE still boasts rapid publication, due in part, to the length of the submissions. The journal publishes significant research on various topics, many of which emphasize the structure-activity relationships of molecular biology.